SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 7.53% Stake in Enlivex Therapeutics

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a shared beneficial ownership of 7.53% of Enlivex Therapeutics Ltd.'s ordinary shares as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 1,781,931 ordinary shares of Enlivex Therapeutics Ltd.
• This represents 7.53% of the company's outstanding ordinary shares.
• The shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital, LLC exercising voting and investment power as its investment manager.
• Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously reported stake.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, potentially influencing investor confidence or perception of institutional interest in Enlivex Therapeutics Ltd.

Key Dates

Keywords

Enlivex Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, SEC Filing, Ordinary Shares, Investment Management, Biotechnology, Pharmaceuticals